Lumos Pharma, Inc.

Lumos Pharma, Inc. could be a weak company given it's low Piotroski F-score. The momentum for this stock is not very good. Lumos Pharma, Inc. is not a good value stock. Lumos Pharma, Inc. is a mediocre stock to choose.
Log in to see more information.
LUMO Fundamental Data by TradingView

News

Lumos Pharma (NASDAQ:LUMO) Trading Down 0.3%
Lumos Pharma (NASDAQ:LUMO) Trading Down 0.3%

Zolmax Lumos Pharma, Inc. (NASDAQ:LUMO - Get Free Report)'s stock price traded down 0.3% during trading on Friday . The company traded as low as $3.70 and last traded at $3.80. 140,982 shares changed hands...\n more…

Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024
Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024

Globe Newswire AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an...\n more…

Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Globe Newswire AUSTIN, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...\n more…

FY2024 EPS Estimates for Lumos Pharma, Inc. Decreased by Cantor Fitzgerald (NASDAQ:LUMO)
FY2024 EPS Estimates for Lumos Pharma, Inc. Decreased by Cantor Fitzgerald (NASDAQ:LUMO)

Zolmax Lumos Pharma, Inc. (NASDAQ:LUMO - Free Report) - Equities researchers at Cantor Fitzgerald decreased their FY2024 EPS estimates for Lumos Pharma in a report released on Monday, August 5th. Cantor...\n more…

Cantor Fitzgerald Equities Analysts Lower Earnings Estimates for Lumos Pharma, Inc. (NASDAQ:LUMO)
Cantor Fitzgerald Equities Analysts Lower Earnings Estimates for Lumos Pharma, Inc. (NASDAQ:LUMO)

Ticker Report Lumos Pharma, Inc. (NASDAQ:LUMO - Free Report) - Cantor Fitzgerald cut their FY2024 EPS estimates for shares of Lumos Pharma in a research report issued on Monday, August 5th. Cantor Fitzgerald...\n more…

Lumos Pharma (NASDAQ:LUMO) Posts Quarterly Earnings Results, Beats Expectations By $0.33 EPS
Lumos Pharma (NASDAQ:LUMO) Posts Quarterly Earnings Results, Beats Expectations By $0.33 EPS

Ticker Report Lumos Pharma (NASDAQ:LUMO - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.93) earnings per share (EPS) for the quarter, topping the consensus estimate of...\n more…